Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies

Abstract

Background:

Several promising new medications containing low-dose estradiol (E2) in combination with a progestin and an additional component, such as gonadotropin-releasing hormone antagonists, are currently being developed for use in pre-menopausal women.

Objective:

This pooled analysis was designed to estimate the thromboembolic safety profile of E2 and its ester, estradiol valerate (E2Val), when used in combined hormonal treatments in a pre-menopausal population.

Methods:

Data regarding users of combined oral contraceptives (COCs) and combined menopausal hormonal therapy (MHT) containing either E2/E2Val or ethinylestradiol (EE) ⩽ 30 µg were retrieved from five large prospective, non-interventional, cohort studies in Europe, US, and Canada with similar study design but differing medication cohorts. Propensity score sub-classification was applied to balance baseline parameters between cohorts and time-to-event analysis of venous thromboembolic events (VTE) was carried out based on the extended Cox model to calculate crude and adjusted hazard ratios (HR).

Results:

(1) Crude incidence rates of VTE were higher in MHT users compared to pre-menopausal COC users, (2) the VTE risk in menopausal users of E2/E2Val-norethindrone acetate was not higher than that in menopausal users of E2/E2Val-progestin (adjusted HR 0.71; 95% confidence interval, 0.41-1.26) and (3) the VTE risk in pre-menopausal users of E2/E2Val-progestin was similar, or lower, than pre-menopausal users of EE⩽30µg-progestin (adjusted HR 0.49; 95% confidence interval, 0.28–0.84).

Conclusion:

Our data presents a solid safety assessment of combined hormonal preparations containing E2/E2Val. We conclude that the risk of E2/E2Val-norethindrone acetate in pre-menopausal users is unlikely to be higher than the known risk of COCs containing EE ⩽ 30 µg-progestin.

Keywords

Epidemiology medical treatment women’s health endometriosis myomas

Get full access to this article

View all access options for this article.

References

ASRM. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107: 43–51.

Stenchever

MA.

Risks of oral contraceptive use in women over 35. J Reprod Med 1993; 38: 1030–1035.

Curtis

Tepper

Jatlaoui

, et al. U.S. Medical eligibility criteria for contraceptive use, 29 July 2016.

Dinger

Bardenheuer

Heinemann

Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric 2016; 19: 349–356.

Grodstein

Manson

Colditz

, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.

Pickar

Archer

Kagan

, et al. Safety and benefit considerations for menopausal hormone therapy. Expert Opin Drug Saf 2017; 16: 941–954.

Harman

Vittinghoff

Brinton

, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011; 124: 199–205.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288: 321–333.

Allison

Manson

Langer

, et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women’s Health Initiative coronary artery calcium study. Menopause 2008; 15: 639–647.

10.

Giordano

Hage

Xing

, et al. Estrogen and cardiovascular disease: is timing everything? Am J Med Sci 2015; 350: 27–35.

11.

Stewart

Black

Choosing a combined oral contraceptive pill. Aust Prescr 2015; 38: 6–11.

12.

Fruzzetti

Trémollieres

Bitzer

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012; 28: 400–408.

13.

H-M

Chang

H-M

Leung

PCK

. Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction. Front Neuroendocrinol. 2021; 60: 100876.

14.

Dinger

Bardenheuer

Assmann

International active surveillance study of women taking oral contraceptives (INAS-OC Study). BMC Med Res Methodol 2009; 9: 77.

15.

Dinger

Heinemann Lothar

, et al. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344–354.

16.

Dinger

Do Minh

Heinemann

Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–339.

17.

Dinger

Möhner

Heinemann

Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 2016; 93: 378–385.

18.

Dinger

Minh

Buttmann

, et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33.

19.

Rothman

Poole

A strengthening programme for weak associations. Int J Epidemiol 1988; 17: 955–959.

20.

Guo

Frase

. Propensity score analysis: statistical methods and applications. (Advanced Quantitative Techniques in the Social Sciences, 11). 2nd ed. Los Angeles: Sage Publications Inc.

21.

Rosenbaum

Rubin

DB.

The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55.

22.

SAS Institute Inc. The SAS system for Windows. Cary, NC: SAS Institute Inc., 2013.

23.

Kat

de, Dam

Onland-Moret

, et al. Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study. BMC Med 2017; 15: 2.

24.

Atsma

Bartelink

Grobbee

, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265–279.

25.

Kuh

Langenberg

Hardy

, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005; 112: 476–485.

26.

As-Sanie

Becker

Johnson

, et al. Efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: phase 3 randomized, double-blind, placebo-controlled study (spirit 2). Fertil Steril 2020; 114: e77.

27.

Lamb

YN.

Elagolix: first global approval. Drugs 2018; 78: 1501–1508.

28.

Pohl

Marchand

Fawkes

, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab 2018; 103: 497–504.

29.

Schlaff

Ackerman

Al-Hendy

, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med 2020; 382: 328–340.

30.

Pohl

Marchand

Bell

, et al. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci 2020; 27: 988–995.

31.

Dinger

Möhner

Heinemann

Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol 2013; 122(4): 800–808.

32.

Junge

Mellinger

Parke

, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011; 31: 573–584.

33.

Klipping

Duijkers

Parke

, et al. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011; 11: 159–170.

34.

Nelson

Parke

Mellinger

, et al. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J Womens Health (Larchmt) 2014; 23: 204–210.

35.

Risk Factors for Venous Thromboembolism (VTE), https://www.heart.org/en/health-topics/venous-thromboembolism/risk-factors-for-venous-thromboembolism-vte (Accessed 24 July 2019).

36.

Fewell

Davey Smith

Sterne

JAC

. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007; 166: 646–655.

37.

Danziger

Zimolzak

AJ.

Secondary analysis of electronic health records: residual confounding lurking in big data: a source of error. Cham, CH, Springer, 2016.